Logo image of TENX

TENAX THERAPEUTICS INC (TENX) Stock Overview

USA - NASDAQ:TENX - US88032L6056 - Common Stock

6.685 USD
-0.14 (-1.98%)
Last: 10/17/2025, 8:00:01 PM
6.81 USD
+0.13 (+1.87%)
After Hours: 10/17/2025, 8:00:01 PM

TENX Key Statistics, Chart & Performance

Key Statistics
Market Cap30.48M
Revenue(TTM)N/A
Net Income(TTM)-31482500
Shares4.56M
Float4.55M
52 Week High8.24
52 Week Low3.9
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.92
PEN/A
Fwd PEN/A
Earnings (Next)11-11 2025-11-11
IPO1993-10-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


TENX short term performance overview.The bars show the price performance of TENX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

TENX long term performance overview.The bars show the price performance of TENX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 -50

The current stock price of TENX is 6.685 USD. In the past month the price increased by 4.29%. In the past year, price increased by 69.24%.

TENAX THERAPEUTICS INC / TENX Daily stock chart

TENX Latest News, Press Relases and Analysis

TENX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.68 405.55B
AMGN AMGEN INC 13.7 160.87B
GILD GILEAD SCIENCES INC 15.87 152.38B
VRTX VERTEX PHARMACEUTICALS INC 24.61 106.87B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 63.14B
REGN REGENERON PHARMACEUTICALS 12.67 61.27B
ARGX ARGENX SE - ADR 91.6 51.94B
INSM INSMED INC N/A 35.04B
ONC BEONE MEDICINES LTD-ADR 5.11 34.76B
BNTX BIONTECH SE-ADR N/A 25.28B
NTRA NATERA INC N/A 24.94B
BIIB BIOGEN INC 8.93 20.97B

About TENX

Company Profile

TENX logo image Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 4 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Company Info

TENAX THERAPEUTICS INC

101 Glen Lennox Drive, Suite 300

Chapel Hill NORTH CAROLINA 27560 US

CEO: Anthony DiTonno

Employees: 4

TENX Company Website

TENX Investor Relations

Phone: 19198552100

TENAX THERAPEUTICS INC / TENX FAQ

What is the stock price of TENAX THERAPEUTICS INC today?

The current stock price of TENX is 6.685 USD. The price decreased by -1.98% in the last trading session.


What is the ticker symbol for TENAX THERAPEUTICS INC stock?

The exchange symbol of TENAX THERAPEUTICS INC is TENX and it is listed on the Nasdaq exchange.


On which exchange is TENX stock listed?

TENX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TENAX THERAPEUTICS INC stock?

11 analysts have analysed TENX and the average price target is 21.42 USD. This implies a price increase of 220.42% is expected in the next year compared to the current price of 6.685. Check the TENAX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TENAX THERAPEUTICS INC worth?

TENAX THERAPEUTICS INC (TENX) has a market capitalization of 30.48M USD. This makes TENX a Nano Cap stock.


How many employees does TENAX THERAPEUTICS INC have?

TENAX THERAPEUTICS INC (TENX) currently has 4 employees.


What are the support and resistance levels for TENAX THERAPEUTICS INC (TENX) stock?

TENAX THERAPEUTICS INC (TENX) has a support level at 6.32 and a resistance level at 7.5. Check the full technical report for a detailed analysis of TENX support and resistance levels.


Should I buy TENAX THERAPEUTICS INC (TENX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TENAX THERAPEUTICS INC (TENX) stock pay dividends?

TENX does not pay a dividend.


When does TENAX THERAPEUTICS INC (TENX) report earnings?

TENAX THERAPEUTICS INC (TENX) will report earnings on 2025-11-11.


What is the Price/Earnings (PE) ratio of TENAX THERAPEUTICS INC (TENX)?

TENAX THERAPEUTICS INC (TENX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.92).


What is the Short Interest ratio of TENAX THERAPEUTICS INC (TENX) stock?

The outstanding short interest for TENAX THERAPEUTICS INC (TENX) is 6.05% of its float. Check the ownership tab for more information on the TENX short interest.


TENX Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TENX. When comparing the yearly performance of all stocks, TENX is one of the better performing stocks in the market, outperforming 90.48% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TENX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TENX. TENX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TENX Financial Highlights

Over the last trailing twelve months TENX reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 96.22% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -29.74%
ROE -30.47%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%85.25%
Sales Q2Q%N/A
EPS 1Y (TTM)96.22%
Revenue 1Y (TTM)N/A

TENX Forecast & Estimates

11 analysts have analysed TENX and the average price target is 21.42 USD. This implies a price increase of 220.42% is expected in the next year compared to the current price of 6.685.


Analysts
Analysts87.27
Price Target21.42 (220.42%)
EPS Next Y76.32%
Revenue Next YearN/A

TENX Ownership

Ownership
Inst Owners64.83%
Ins Owners0.21%
Short Float %6.05%
Short Ratio4.82